TuHURA Biosciences, Inc.

NASDAQ:HURA

Biotechnology

Healthcare
$1.37 +6.37%

+$0.14 today

Market cap
$87.31M
Beta
0.01
P/E (TTM)
-4.6
EPS (TTM)
-$0.52
52W Low $0.41High $3.90

Volume 0.19M

Average 0.85M

HURA Other Working Capital

Cash effect of changes in other operating assets and liabilities.

TuHURA Biosciences, Inc.NASDAQ: HURA

Other Working Capital · Q1 FY2026 · quarter ended Mar 2026

Other working capital turns negative

Q1 FY2026 other working capital was -$148.07K, compared with $41.61K a year earlier. Trailing-twelve-month other working capital was -$3.78M.

Context

  • Other working capital increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly other working capital holds near -$148.07K or moves back toward the trailing-twelve-month quarterly average of -$945.97K.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$148.07K-132.2% QoQ
Last fiscal yearDec 2025
-$3.15M-195.8% YoY
LTMMar 2026
-$3.78M— YoY
Other Working Capital past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-455.8%——
1 year-195.8%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Other Working Capital history

USD · from the cash flow

Latest · FY2025
(3.15M) USD
Year-over-year change
-195.8%

Other Working Capital vs competitors

How HURA compares with its peers on the latest reported figures

  • HURA's LTM Mar 2026 other working capital of $3.78M is the 6th largest of the 9 companies compared; the peer median is $3.92M.
HURA Competitors Peer median
Other Working Capital for HURA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
MCRBSeres Therapeutics, Inc.LTM Mar 2026$20.07M +2771.2%+9.4%1749.8%
SPROSpero Therapeutics, Inc.LTM Mar 2026$12.54M -150.3%—22.9%
IRDOpus Genetics, Inc.LTM Mar 2026$5.88M -232.3%+192.8%49.1%
ABOSAcumen Pharmaceuticals, Inc.LTM Mar 2026$4.04M -138.9%——
AGENAgenus Inc.LTM Mar 2026$3.8M -152.4%-31.7%3.1%
HURATuHURA Biosciences, Inc.LTM Mar 2026$3.78M ———
INOInovio Pharmaceuticals, Inc.LTM Mar 2026$2.17M -37.3%-32.4%—
SEERSeer, Inc.LTM Mar 2026$235K -73.3%—1.6%
CGTXCognition Therapeutics, Inc.LTM Mar 2026$60K -94.3%-44.2%—
Peer median (excluding HURA) $3.92M-116.6%-31.7%22.9%

Competitors are the stored peer set for HURA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(7.02M)(9.37M)(29.32M)(21.68M)(30.05M)
Depreciation & Amortization380.69K373.09K177.38K116.71K71.27K
Deferred Income Tax00000
Stock-Based Compensation654.53K218.28K478.89K1.96M6.42M
Change in Working Capital(55K)1.56M486.92K3.29M(3.15M)
Accounts Receivables00000
Inventory00000
Accounts Payables00000
Other Working Capital(55K)1.56M486.92K3.29M(3.15M)
Other Non-Cash Items(527.06K)(294.07K)21M1.59M(924.51K)
Operating Cash Flow(6.56M)(7.51M)(11.95M)(14.73M)(27.63M)
Capital Expenditures(3.28K)(232K)(79.22K)(57.91K)(76.08K)
Acquisitions (Net)00(1.22M)(5.99M)(1.26M)
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities00000
Investing Cash Flow(3.28K)(36.28K)(1.3M)(6.05M)(1.34M)
Debt Repayment294.07K(350K)2.69M28.57M616.98K
Common Stock Issued5.6M1.9M10.58M5M21.92M
Common Stock Repurchased00(24.75K)00
Dividends Paid(8K)(8K)(6K)0(8.36K)
Other Financing Activities8K00(3.8M)(2.61M)
Financing Cash Flow7.04M16.25M2.66M29.77M19.93M
Effect of Forex Changes00000
Net Change in Cash477.91K8.71M(10.59M)8.99M(9.04M)
Free Cash Flow(6.57M)(7.54M)(12.03M)(14.79M)(27.71M)

TuHURA Biosciences, Inc.

NASDAQ:HURA

Intrinsic Alpha fair value

Locked

Current Price

$1.37

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.